BBBianca Muylaert Barrett

Bianca Muylaert Barrett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bianca Muylaert Barrett has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Retrospective Review of Pediatric Psoriasis and TNF-Inhibitor Induced Psoriasiform Disease in Patients With Skin of Color

    by Bianca Muylaert Barrett, Elena Pastukhova, Perla Lansang, Cathryn Sibbald

    Background: Psoriasis affects ~3% of the adult U.S. population, with known differences in prevalence, presentation, and treatment outcomes across racial and ethnic groups. In pediatric populations, disparities in psoriasis recognition may lead to delayed diagnosis and undertreatment, especially in patients with skin of color (SoC). Objectives: To compare clinical presentation and treatment patterns in pediatric patients with psoriasis with and without SoC at a single tertiary-care pediatric center. Methods: We conducted a retrospective, case–control cohort study of patients diagnosed with psoriasis (including TNF-associated psoriasis) before age 18 at SickKids Hospital (January 2008-March 2024). Inclusion criteria were systemic treatment before or after diagnosis of psoriasis and available photo documentation. Patients were stratified by skin phototype based on the Massey-Martin Scale for SoC. Demographics, clinical features, and treatment patterns were compared between SoC and non-SoC groups. Results: Among 115 patients, 42.6% were classified as SoC. Scalp involvement ( P = .008), inflammatory bowel disease ( P = .05), and arthritis were more common in non-SoC patients. SoC patients had a shorter time to diagnosis and were more likely to receive cyclosporine initially and methotrexate overall. Non-SoC patients had higher biologic use throughout care (77.2% vs 63.2%). Topical corticosteroids were the most prescribed treatment across both groups. Conclusions: Pediatric patients with and without SoC showed distinct trends in disease presentation and management. Differences in clinical presentation and medication use highlight the need for increased awareness of psoriasis manifestations in diverse skin types. Prospective studies with standardized assessment tools could help addressing the differences described in this study.

  • Open Access

    Dual biologic therapy in a patient with severe psoriasis and psoriatic arthritis, using guselkumab and bimekizumab: A case report and review of the literature

    by Bianca Muylaert Barrett, Milena Music, Geeta Yadav

    Dual biologic therapy is not often used in psoriasis and psoriatic arthritis due to cost and safety concerns, with limited literature supporting its use. We present a case of a 31-year-old man with severe plaque psoriasis and erosive psoriatic arthritis, refractory to multiple therapies. While guselkumab improved skin symptoms, joint inflammation persisted. Given the patient’s reluctance to discontinue guselkumab and his poor response to prior therapies, bimekizumab was added. This combination led to near-complete skin clearance and significant joint improvement within 3 months, with sustained benefits and no adverse effects at 17 months. This case illustrates how targeting multiple points in the interleukin-23/interleukin-17 pathway can improve outcomes in patients unresponsive to monotherapy. Dual biologic therapy may be a viable option for select patients with complex disease, though further research is needed to evaluate its long-term safety and efficacy.